Basit öğe kaydını göster

Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial

dc.contributor.authorde Winter, Jobst
dc.contributor.authorMurphy, Sabina A.
dc.contributor.authorMcCabe, Carolyn H.
dc.contributor.authorGibson, C. Michael
dc.contributor.authorZorkun, Cafer
dc.contributor.authorMolhoek, Peter
dc.contributor.authorZmudka, Krzysztof
dc.contributor.authorGreenberg, Mark
dc.contributor.authorMueller, Hiltrud
dc.contributor.authorWesdorp, Jan
dc.contributor.authorLouwerenburg, Hans
dc.contributor.authorNiederman, Alan
dc.contributor.authorWestenburg, Jaap
dc.contributor.authorBikkina, Mahesh
dc.contributor.authorBatty, John
dc.date.accessioned2022-02-18T11:21:38Z
dc.date.available2022-02-18T11:21:38Z
dc.date.issued2006
dc.identifier.citationGibson C. M. , Zorkun C., Molhoek P., Zmudka K., Greenberg M., Mueller H., Wesdorp J., Louwerenburg H., Niederman A., Westenburg J., et al., "Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial", JOURNAL OF THROMBOSIS AND THROMBOLYSIS, cilt.22, sa.1, ss.13-21, 2006
dc.identifier.issn0929-5305
dc.identifier.othervv_1032021
dc.identifier.otherav_ee07889f-4208-41d3-b39d-bf580c301fb8
dc.identifier.urihttp://hdl.handle.net/20.500.12627/181019
dc.identifier.urihttps://doi.org/10.1007/s11239-006-8080-1
dc.description.abstractBackground: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2].
dc.language.isoeng
dc.subjectHematology
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectKardiyoloji
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectSağlık Bilimleri
dc.subjectHealth Sciences
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.subjectPERİFERAL VASKÜLER HASTALIĞI
dc.subjectTıp
dc.titleDose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial
dc.typeMakale
dc.relation.journalJOURNAL OF THROMBOSIS AND THROMBOLYSIS
dc.contributor.department, ,
dc.identifier.volume22
dc.identifier.issue1
dc.identifier.startpage13
dc.identifier.endpage21
dc.contributor.firstauthorID3374105


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster